drugset / Trial / NCT05942365

A Drug Interaction Study Assess the Effects of ZSP1273 Tablets on the Pharmacokinetics of Warfarin and Midazolam

NCT05942365

Phase 1 Completed 28 enrolled Guangdong Raynovent Biotech Co., Ltd
NaSingle-groupOpen-labelBasic science

Summary

This study is a single-center, open label phase I clinical study to characterize the DDIs potential of ZSP1273 With Warfarin and Midazolam in Chinese healthy participants. This study also aims to evaluate the safety and tolerability of ZSP1273 in the presence of Warfarin and Midazolam.

Timeline

Start
2023-06-25
Primary completion
2023-07-21
Completion
2023-08-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Midazolam Small molecule Oral
Subject Onradivir Small molecule
Subject Warfarin Small molecule Oral

Indications

No indication recorded.